$IMGN pretty safe bet... shot themselves in the foot with the original trial which had some good data... now it’s just replicating basically the same trial with some different patient population and endpoint... gonna be 15 plus after approval, plus IMGN 632 is also a valuable asset
  • 3
  • 2